Market Access Agenda in Europe

Video interview on EU HTA

Mon, 2024 / 06 / 03
Insightful discussion with Prof. Dr. Matthias P. Schönermark, founder and managing director of SKC, and Oznur Seyhun, Partner & Anchorwoman at Market Access Today.

Video interview on EU HTA

You can watch the video here

Please click to load Video from YouTube. Personal data may be transferred to the provider.


The interview covers the following topics:

  • Introduction to Prof. Dr. Matthias P. Schönermark: Discover the impressive career journey of Prof. Schönermark and his significant contributions to the field of health technology assessment (HTA).
  • Impact of European HTA Regulation: With the European Health Technology Assessment Regulation now effective for oncology drugs and advanced therapy medicinal products (ATMPs), Prof. Schönermark discusses the anticipated impacts on industry practices and patient access.
  • Implications of the Implementing Act: After some delays, the Implementing Act on the Design of Joint Clinical Assessments was recently published in April. Learn about its implications and how it is prepared to enhance the implementation of the European HTA Regulation across Member States.
  • Future Trends in Patient Access: Prof. Schönermark outlines the trends he foresees in Europe regarding securing adequately funded patient access and how he sees the European HTA fitting within the broader organization. 

Source: Market Access Today

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

EU HTA: European Health Technology Assessment (JCA)

Achieve planning security: With us you can align your projects and your resource planning comprehensively and at an early stage on EU HTA and its implications for market access.


One HTA to assess them all 2.0 - The strategic perspective on EU HTA updated
to the top